2-47403322-C-T
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PM2PM5PP3_Strong
The ENST00000233146.7(MSH2):c.131C>T(p.Thr44Met) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000688 in 1,453,272 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. T44K) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000233146.7 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MSH2 | NM_000251.3 | c.131C>T | p.Thr44Met | missense_variant | 1/16 | ENST00000233146.7 | NP_000242.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MSH2 | ENST00000233146.7 | c.131C>T | p.Thr44Met | missense_variant | 1/16 | 1 | NM_000251.3 | ENSP00000233146 | P1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 exomes AF: 0.00000438 AC: 1AN: 228568Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 124826
GnomAD4 exome AF: 6.88e-7 AC: 1AN: 1453272Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 722234
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 12, 2022 | The p.T44M variant (also known as c.131C>T), located in coding exon 1 of the MSH2 gene, results from a C to T substitution at nucleotide position 131. The threonine at codon 44 is replaced by methionine, an amino acid with similar properties. This alteration was detected in a colorectal cancer family but not fulfilling the Amsterdam criteria (Bisgaard ML et al. Hum Mutat, 2002 Jul;20:20-7). This alteration has demonstrated mismatch repair (MMR) activity similar to wild-type or benign controls in functional studies from multiple independent laboratories (Gammie AE et al. Genetics, 2007 Oct;177:707-21; Christensen LL et al. Fam Cancer, 2009 Aug;8:489-500; Martinez SL et al. Proc Natl Acad Sci U S A, 2010 Mar;107:5070-5; Drost M et al. Hum Mutat, 2012 Mar;33:488-94). A study of the functional significance of MSH2 missense variants using CRISPR-Cas9 gene editing in human embryonic stem cells suggests this alteration is proficient at DNA repair function, damage response signaling and protein stability (Rath A et al. Hum Mutat, 2019 11;40:2044-2056). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Uncertain significance, criteria provided, single submitter | curation | Sema4, Sema4 | Nov 03, 2021 | - - |
Hereditary nonpolyposis colorectal neoplasms Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 20, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at